Gland FDA Wednesday, October 16, 2019 +0.20 Positive

FDA Approves NEOSTIGMINE METHYLSULFATE — Gland Pharma Limited

Gland Pharma Limited announced that the FDA has approved the ANDA for Neostigmine Methylsulfate, a cholinesterase inhibitor indicated for the reversal of neuromuscular blockage following surgery. This approval allows for the intravenous launch of the generic, offering the U.S. market a bioequivalent alternative and enabling the manufacturer to target competitive share in this critical perioperative care space.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed